NCT04541420已完成不适用
An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 208
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- •Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug
- •Available medical history.
排除标准
- •Incomplete medical history.
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
Adverse events
时间窗: 6 weeks
Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerMetastatic Breast CancerNCT05206656Hunan Cancer Hospital80
已完成
不适用
Extended Treatment in Metastatic Breast Cancer With EribulinBreast CancerNCT02769364Eisai Limited45
已完成
不适用
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesBreast CancerNCT01142661Eisai Inc.9
Unknown
不适用
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast CancerBreast CancerNCT04683445Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University80
已完成
2 期
First Line Metastatic Breast Cancer Treatment (ESMERALDA)Metastatic Breast CancerNCT01941407ARCAGY/ GINECO GROUP61